Share This Author
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.
Human infection with a novel avian-origin influenza A (H7N9) virus.
Novel reassortant H7N9 viruses were associated with severe and fatal respiratory disease in three patients, and all three patients died.
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
A novel bat-borne CoV was identified that is associated with severe and fatal respiratory disease in humans and the amino acid sequence of the tentative receptor-binding domain resembles that of SARS-CoV, indicating that these viruses might use the same receptor.
Clinical findings in 111 cases of influenza A (H7N9) virus infection.
The presence of a coexisting medical condition was the only independent risk factor for the acute respiratory distress syndrome (ARDS) during the evaluation period, and the novel H7N9 virus caused severe illness, including pneumonia and ARDS, with high rates of ICU admission and death.
Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.
Surveillance of the 2009 H1N1 virus in China shows that the majority of those infected have a mild illness, and the duration of infection may be shortened if oseltamivir is administered.